Background: Familial hypertrophic cardiomyopathy (HCM) is an autosomal dominant disease characterized by ventricular hypertrophy, myocellular disarray, arrhythmias, and sudden death. Mutations in several contractile proteins, including cardiac myosin heavy chains, have been described in families with this disease, leading to the hypothesis that HCM is a disease of the sarcomere. Materials and Methods: A mutation in the myosin heavy chain (Myh) predicted to interfere strongly with myosin's binding to actin was designed and used to create an animal model for HCM. Five independent lines of transgenic mice were produced with cardiac-specific expression of the mutant Myh. Results: Although the mutant Myh represents a small proportion (1-12%) of the heart's myosin, the mice exhibit the cardiac histopathology seen in HCM patients.
INTRODUCTION
Familial hypertrophic cardiomyopathy (HCM) is a clinically heterogeneous heart disease with a dominant mode of inheritance (1) . The potential for understanding the pathogenesis of HCM advanced with the identification of mutations in the ,B myosin heavy chain (Myh) gene in two kindreds with HCM (2, 3) . Since then 40 f Myh mutations, primarily in the "motor" domain of the molecule, have been reported (4) . The identification of mutations in additional muscle structural proteins (cardiac troponin T, a-tropo-myosin and cardiac myosin binding protein C; [5] [6] [7] [8] ) has shown that HCM is also genetically heterogeneous and led to the hypothesis that HCM is a disease of the sarcomere (5) . Although the genetic evidence for contractile protein defects in HCM is unequivocal, the link between these mutations and the clinical phenotype remains unclear. The dominant mode of inheritance may imply that the mutant protein acts as a dominant negative, interfering with the function of the wild-type protein. Several lines of evidence support this hypothesis. Myosin purified from HCM patients (which is a mixture of wild-type and mutant protein) exhibits decreased motility in in vitro motility assays (9) . Biochemical analysis of a mutant allele (Arg4O3Gln) demonstrates a defect in actin-acti- 557 vated ATPase activity and decreased motility in an in vitro assay (10) . In addition, the mutant Myh exhibits a dominant effect when mixed with wild-type protein, disproportionately slow- ing the velocity of the mixture (10) .
It remains to be established whether HCM mutations exhibit a dominant negative mode of action in vivo. In addition, the often dissimilar clinical phenotypes exhibited by affected members of the same family ( 11) or different families with identical myosin mutations (12) suggest that other factors contribute to the clinical course of the disease. Since addressing these questions in a patient population is difficult, such studies would benefit from an experimental animal model. Feline, canine, and porcine hypertrophic cardiomyopathy have been described (13, 14) . However, a dominant inheritance pattern has not been demonstrated in these species, and the molecular defect has not been described, raising the possibility of a different molecular basis for HCM in these animals. Recently, a mouse model of HCM has been described which mimics several aspects of HCM in humans, namely the appearance of myocellular disarray, fibrosis, and cardiac dysfunction (15) . However, these animals also exhibit left atrial enlargement in the absence of ventricular hypertrophy, features not typically seen in the human condition. Consequently, these animals may not prove to be suitable for studying many aspects of HCM pathogenesis, necessitating other animal models of HCM. Toward this end, we have created transgenic mouse lines which phenotypically are virtually identical to human HCM and allow the impact of contractile protein mutations on the heart to be analyzed and factors contributing to the disease's natural history to be determined.
MATERIALS AND METHODS
Production of Transgenic Mice Transgenes were construct using standard cloning techniques. The transgene coding region consists of a rat a Myh cDNA (16) RNAase Protection RNA was purified using the guanidinium-acid phenol method (18) . An antisense riboprobe was generated using the Promega Riboprobe kit (Promega, Madison, WI, U.S.A.) and purified by guanidinium-acid phenol extraction followed by isopropanol precipitation. A five hundred thousand-counts per minute probe was combined with 3 (19) were electrophoretically separated on 6% SDS-polyacrylamide gels according to Laemmli (20) . Electrophoresis was continued until the Myhs had migrated approximately 8 cm through a 11-cm separating gel. Immunoblotting was performed as described (21) and chemiluminescent images were quantified using a Molecular Dynamics laser densitometer. The anti-a Myh monoclonal antibody, BAG5 (22) (27) . Five independent transgenic lines were established and cardiac-specific expression of the transgene mRNA was confirmed by ribonuclease (RNase) protection analysis ( Fig. 2 ). Long exposures revealed very low levels of the endogenous mouse a Myh in the lung, as has been previously described (28) . However, transgene expression was detected only in the heart. Transgene message was abundant in the hearts of these mice and was found at 26-50% of the endogenous mouse Myh levels (not shown).
If these transgenic mice are to function as a model for HCM they should exhibit several phenotypic features found in most individuals with the disease (29, 30) . These include myocyte hypertrophy, myocellular disarray, interstitial fibrosis, and small vessel coronary disease (2, 31) . Hearts from each transgenic line were examined at 12-14 weeks of age for evidence of these features. In all cases the atria were normal but significant cardiac histopathology was evident in the left ventricle (Fig. 3) . In a few animals, some abnormal myocytes were seen in the right ventricle but the vast majority of hypertrophied cells were found in the left ventricle. Foci of myocellular disarray were found throughout the left ventricle accompanied'by evidence of increased matrix accumulation (Fig. 3B ). When areas with myocellular disarray were identified and then examined at the electron microscope level, several abnormalities were seen (Fig. 4) . Degenerating myofibrils, prominent collagen deposits and z-line streaming were apparent. It is interesting to note that severely damaged myocytes often were adjacent to apparently normal cells. In these instances, intact myofibrils were absent near the intercalated discs, implying a lack of force transmission between the adjacent myo- cytes. These electron micrographs are virtually indistinguishable from published micrographs of skeletal muscle biopsies from HCM patients (32, 33) .
Small vessel coronary disease, seen histopathologically as thickening of the medial and intimal layer of small coronary vessels, is found in many patients with HCM (3 1) and is also present in feline and porcine HCM (13, 14) . Abnormal coronary vessels were found in the hearts of all transgenic mouse lines (Fig. 3 , compare C and D). Not all vessels were hypertrophied, as evidenced by the presence of normal and abnormal vessels within the same animal. Such vessel-to-vessel heterogeneity is also seen in humans (31) . Mutant a Myh expression was not detected in smooth muscle rich tissues such as uterus (Fig. 2) suggesting that it also is not expressed in the smooth muscle layer of the coronary arteries. The smooth muscle hypertrophy seen in small coronary arteries is most likely the result of a compensatory response of the vasculature to dysfunctional cardiac myocytes. While all five lines of mice exhibit histopathology characteristic of the disease, two were relatively mild and three were quite strong in phenotype at the microscopic level. Two transgenic lines (lines 131 and 140) were selected as examples of mild and strong phenotypes, respectively, and retained for further study.
Actin and myosin are normally found in a precise ratio in muscle and alterations in this Tg Myh stoichiometry could have profound effects. To determine whether expression of the mutant Myh perturbed contractile protein stoichiometry in these transgenic mice, cardiac myofibrils were prepared from transgenic mice (131 and 140 lines). The ratio of myosin to actin in these preparations was determined by densitometry and compared with control mouse cardiac myofibrils (not shown). The myosin/actin rations were found to be identical, although very small alterations undetectable by our analysis cannot be ruled out. The amount of transgene protein in heart homogenates was determined by SDSacrylamide gel electrophoresis followed by immunoblotting and densitometry. Acrylamide gels were run which optimized the size differences between the mutant and endogenous wild type species. As shown in Fig. 5 , the mutant protein comprises 10-12% of the total myosin in Line 140 and 0.6-2.5% in Line 131. Identical results were obtained whether heart homogenates ( Fig. 5 ) or purified myofibrils (not shown) were examined. The low levels of mutant protein, in conjunction with the apparently normal actin/ myosin stoichiometry, suggest that the severe phenotype is due to the dominant effect of the mutant such that a relatively small number of mutant polypeptides exert a "drag" on sarcomere function. Consistent with this conclusion is the report that a mixture of mutant (Arg4O3Gln) and wild-type myosin exhibits the properties of the mutant unless the wild-type constitutes greater than 60% of the mixture (10) .
Atria, left ventricle and right ventricle weights were determined in age-matched transgenic mice (12 weeks and 8 months of age) with negative littermates serving as controls (Table 1 and Fig. 6 ). At (Fig. 2) .
gested that the 140 line hearts had overall dimensions that were much greater than the controls (Fig. 7, A and B ). This group exhibited significant chamber dilation (Fig. 7) . In control hearts the left ventricular cavity was a normal crescent shape (seven out of seven hearts examined) while in all 8-month 140 line males (five hearts examined) the left ventricular cavity was dilated and almond-shaped (Fig. 6 ).
DISCUSSION
Molecular genetic analysis has revealed that hypertrophic cardiomyopathy is often associated with mutations in genes encoding contractile proteins. This has led to the hypothesis that HCM is a disease of the sarcomere (5). However, the exact relationship between mutant contractile proteins and the phenotype remains unclear.
Characterizing HCM pathogenesis at a cellular and molecular level may provide the information needed to address this question. We have created five independent transgenic mouse lines with cardiac-specific expression of a mutant Myh. Like human HCM, the animal model shows left ventricular hypertrophy, myocyte hypertrophy, myocellular disarray, fibrosis, and small vessel coronary disease. Based on these findings, the transgenic mice are a good model for HCM and their analysis provides insight into the mechanisms involved in developing the disease phenotype. It is clear that mutant contractile proteins are the initial insult in the development of HCM, but patients do not die purely as the result of sarcomeric dysfunction. We suspect that mutations in f3 Myh, cardiac troponin T, a-tropomyosin, and cardiac myosin binding protein C trigger a patho- Since transgenic mice are an excellent tool for analyzing phenotypic changes over time, it was interesting to note that in the 140 line older male and female mice exhibit distinct phenotypes. While the cardiac hypertrophy was increased in older female animals, male 140 line mice exhibited significant dilation of the left ventricle (Fig. 7) . Although sex-specific differences in the HCM phenotype have not been reported in humans, clinical heterogeneity is a hallmark of this disease. In addition, HCM patients often exhibit progressive wall thinning or relative ventricular dilation as they age (38) (39) (40) (41) (C and D) . In this position, the atria are hidden behind the two halves of the heart, the left ventricular free wall is distal and the right ventricular free wall is medial to the vertical axis.
disease is cardiac sudden death (41) . The development of sex-specific phenotypes in the 140 line animals may provide a fortuitous tool for deciphering the factors contributing to the clinical course of the disease as well as the molecular mechanisms leading to dilated cardiomyopathy.
Although cardiac disease in a small mammal is inherently different from that seen in humans, the mouse allows analyses of disease at molecular and cellular levels impossible in humans. Mouse models of cardiac hypertrophy, such as those resulting from overexpression of protooncogenes (42, 43) or calmodulin (44) in the heart demonstrate some similarities to the hypertrophy in the transgenic animals described in this report. However, the hypertrophic stimulus in those animals is quite different from that in the HCM mice. In addition, while one recently described mouse model for HCM (15) genetically most closely resembles the human disease, phenotypically it displays substantial difference, namely profound left atrial enlargement in the absence of ventricular hypertrophy. The difference in phenotype may be due to the nature of the mutation, the genetic background, or both. Nevertheless, insight into the basic mechanisms underlying cardiac hypertrophy may be gained from comparing the different models. In addi-A tion, the knowledge gained from studying cardiac pathogenesis in the HCM mice should impact our knowledge of human HCM. The power of using a combined molecular and morphological analysis of these transgenic mice and the ability to breed them with other genetically altered mouse lines should facilitate the search for the elements involved in the pathogenesis of HCM and the identification of potential therapeutic targets.
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